WO1999063061A1 - Obtention de lignees de cellules de souches embryonnaires issues de cellules somatiques par reconstruction des embryons et ablation selective - Google Patents

Obtention de lignees de cellules de souches embryonnaires issues de cellules somatiques par reconstruction des embryons et ablation selective Download PDF

Info

Publication number
WO1999063061A1
WO1999063061A1 PCT/GB1999/001738 GB9901738W WO9963061A1 WO 1999063061 A1 WO1999063061 A1 WO 1999063061A1 GB 9901738 W GB9901738 W GB 9901738W WO 9963061 A1 WO9963061 A1 WO 9963061A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
animal
embryo
stem
Prior art date
Application number
PCT/GB1999/001738
Other languages
English (en)
Inventor
James Mcwhir
Original Assignee
Biotechnology And Biological Sciences Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnology And Biological Sciences Research Council filed Critical Biotechnology And Biological Sciences Research Council
Priority to AU42755/99A priority Critical patent/AU4275599A/en
Publication of WO1999063061A1 publication Critical patent/WO1999063061A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/04—Cells produced using nuclear transfer

Definitions

  • the present invention relates to a method for generating animal stem cells and cell lines, particularly embryonic stem cells and embryonic germ cells, and to uses of the stem cells produced in medicine.
  • Stem cells are progenitor cells which have the capacity both to self-renew and to differentiate into mature somatic tissues.
  • Stem cells may be founder cells for embryonic or other cell lineages, for example in haematopoeisis and myogenesis.
  • ES cells are rapidly dividing cultured cells which retain in culture, the ability to give rise to all embryonic lineages (totipotency).
  • ES cells are isolated from cultured embryos in a process which releases a normally transient cell population from the controlling influence of other lineages within the embryo. Embryos are usually taken at the blastocyst stage immediately following the differentiation of the embryo into trophectoderm and inner cell mass. They can be grown in large numbers in the undifferentiated state and following their reintroduction to an early embryo, will resume their normal programme of differentiation to contribute to all embryonic tissues including the germ cells. ES cells have the innate capacity to proliferate indefinitely without any form of oncogenic transformation.
  • ES cells are therefore widely used as a means to effect genetic changes in the mouse.
  • the ability to apply somatic cell genetics to a cultured cell population allows the use of gene targeting to effect precise gene modifications which can include gene inactivation, subtle sequence changes or the precise placement of new genes into active sites in the genome (Bradley et al Bio /Technology 10 534-539 (1992)).
  • Functionally similar cells to ES cells known as embryonic germ (EG) cells have been generated by the culture of primordial germ cells taken from later stage embryos (Matsui et al Cell 70 841-847 (1992); Labonsky et al Development 120 3197-3204 (1994)).
  • blastocyst stage embryos are flushed from the uterus and then cultured in medium over a layer of mitotically inactivated fibroblasts, "feeder" cells. Over a few days blastocysts attach and spread onto the feeder layer, exposing cells of the inner cell mass. The inner cell mass of some explants proliferate forming clumps of undifferentiated cells. This portion of each explant is manually isolated, disaggregated and replated onto a new feeder layer. Colonies of cells form, usually composed of several cell types. Any colonies with ES morphology are further isolated, disaggregated and replated. Repeating this through several passages can result in a homogenous population of ES cells.
  • a vital part of the derivation process is the physical separation of ES cells away from differentiated tissues, e.g. trophectoderm and endoderm. These arise from differentiated cells of the explanted embryo and also from spontaneous differentiation of ES cells. Endoderm is commonly the first product of ES cell differentiation and cells of this type tend to lie closely apposed to undifferentiated ES cells. The proximity of differentiated cells induces further differentiation of ES cells. The presence of feeder cells is believed to be helpful during the first stages of ES cell derivation to reduce spontaneous differentiation of undifferentiated cells. However, the mechanism involved is only partially defined. Established ES cell lines can usually be grown successfully in the absence of a feeder layer (Magin et al. , Nuc. Acids. Res.
  • ES lines can be obtained from 5-10% mouse blastocysts using strain 129Sv (Robertson, E.J., M.H. Kaufman., Bradley, A and M.J. Evans. 1983. "Isolation, Properties and Karyotype Analysis of Pluripotential (EK) Cells from Normal and Parthenogenetic Embryos" in: “Teratocarcinoma Stem Cells", Cold Spring Harbor Conferences on Cell Proliferation 10 647-663. Eds. Martin, G.R., L. Silver and S. Strickland.
  • nuclear transfer can be employed, not as an alternative to ES or EG cells, but to enhance the opportunities for stem cell isolation, particularly ES/EG isolation, in a broad range of species.
  • a method for generating animal stem cells from an animal embryo in culture comprising the steps of reconstituting an animal embryo by transferring the nucleus of a donor cell into a suitable recipient cell followed by selective killing of differentiated cells of the reconstituted embryo.
  • the animal stem cells may be pluripotent) stem cells, embryonic stem (ES) cells, embryonic germ (EG) cells (primordial germ cell-derived or PGC-derived cells), somatic stem/progenitor cells, haematopoietic stem cells, epidermal stem cells or neuronal stem cells.
  • a totipotent cell can direct the development of a whole animal (when constructing embryos by nuclear transfer from a donor cell into a recipient cell, such as an enucleated oocyte, it is the nucleus of the donor cell which is totipotent). This includes directing the development of extra- embryonic lineages, i.e. the placenta.
  • a fertilised zygote and in some species individual blastomeres are also totipotent.
  • a pluripotent or multipotent cell i.e. an embryonic stem cell
  • the animal stem cells may be embryonic stem (ES) cells or embryonic germ (EG) cells.
  • the invention is applicable to the generation of stem cells from all animals, including mammals, birds, such as domestic fowl, amphibian species and fish species. In practice, however, it will be to mammals, particularly placental mammals, including non-human primates and humans, that the invention is presently envisaged to have an important use in the preparation of stem cells or stem cell lines from which differentiated cells can be produced to treat diseases, particularly diseases characterised by a loss, absence or reduction of normal cell function. The invention is also likely to find application to the generation of stem cells from non-human mammals, e.g.
  • ungulates particularly economically important ungulates such as cattle, sheep, goats, water buffalo, camels and pigs, both as a means for cloning animals and as a means for generating transgenic or genetically modified animals.
  • the invention is also likely to be applicable to other economically important animal species such as, for example, horses, llamas or rodents e.g. rats or mice, or rabbits.
  • transgenic in relation to animal stem cells, should not be taken to be limited to referring to animal cells containing in their DNA one or more genes from another species, although many transgenic animal stem cells will contain such a gene or genes. Rather, the term refers more broadly to any animal stem cell whose DNA has been the subject of technical intervention by recombinant DNA technology either prior to embryo reconstruction by manipulation of the donor cell or after manipulation by manipulation of a stem cell generated according to a method of the present invention. So, for example, an animal stem cell in whose DNA an endogenous gene has been deleted, duplicated, activated or modified is a transgenic animal stem cell for the purposes of this invention as much as an animal stem cell to whose DNA an exogenous DNA sequence has been added.
  • the donor nucleus is genetically modified.
  • the donor nucleus may contain one or more transgenes and the genetic modification may take place prior to nuclear transfer and embryo reconstitution.
  • micro-injection analogous to injection into the male or female pronucleus of a zygote, may be used as a method of genetic modification, the invention is not limited to that methodology: mass transformation or transfection techniques can also be used e.g. electroporation, viral transfection or lipofection.
  • Transgenesis may be achieved, for example, by DNA microinjection or transfection.
  • Microinjection methods involve DNA microinjection into zygotes or early cleavage stage embryos. Methods for transgenic mice are described in detail by Hogan et al , "Manipulating the Mouse Embryo: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1986). DNA microinjection using essentially the same techniques has been successfully applied to other species, including farm animals, albeit with reduced efficiency (reviewed by Wall et al. , Theriogenology 38 337-357 (1992) and Wilmut et al , Reprod. Fert. Suppl. 43 265-275 (1991)).
  • Transgenic animal stem cells may be identified by appropriate DNA analysis of biopsies.
  • transgene constructs will necessarily be the only transgene constructs integrated into the animal stem cell's DNA, although in many cases they will be the only ones.
  • an expression construct simply to be introduced into the embryo cell(s) by any suitable means, such as microinjection (see, for example, Burdon et al , Mol. Reprod. and Dev. 33 436-442 (1992)). Although such a construct may not survive for long in the absence of replication sequences (and in the absence of integration) it may persist for long enough for the method of the first aspect of the invention to be practised on the embryo. In any event, the relatively short duration of a non-integrating, non-replicating construct may actually be an advantage, as no particular steps are needed to remove the construct if its continued presence is either not desired, or where its removal is obligatory. The latter case would apply to stem cells containing a toxin gene under the control of a promoter causing specific expression in differentiated cells. Such a construct is normally to be removed before stem cells can participate in embryo development.
  • a third possibility is that the expression construct may be present in the embryonic cells coupled to sequences that give rise to episomal replication.
  • Episomal vectors of this type have been derived from bovine papilloma virus (Mathias et al. , EMBO J. 2 1487- 1492 (1983)) and adenovirus (Quantin et al , Proc. Nat 'I. Acad. Sci. 89 2581-2584 (1992)).
  • bovine papilloma virus Mathias et al. , EMBO J. 2 1487- 1492 (1983)
  • adenovirus Quantin et al , Proc. Nat 'I. Acad. Sci. 89 2581-2584 (1992)
  • stem cell preferably ES cell or EG cell
  • isolation depend upon expression of stem cell-specific salvage transgenes which preserve the stem cell lineage under generally lethal selection conditions or differentiated cell-specific expression of toxin transgenes. Integration and maintenance of the transgene after ES isolation is probably unimportant and may be undesirable.
  • a short term transfection system such as lipofection (Feigner et al , Nature 337 387-388 (1989)) is therefore suited to this approach in large animals - particularly where transient infection can be effected under near-physiological conditions (Brunette et al, Nucl. Acids Res. 20 1151 (1992)).
  • Lipofection involves the spontaneous association of DNA with a liposome containing a cationic lipid, which then fuses with the cell membrane, leading to internalisation of DNA. Suitable liposome preparations are commercially available.
  • lipofection as a means of transgenesis in the context of the present invention.
  • lipofection is a relatively benign treatment which can be applied repeatedly without toxicity. Repeated lipofection will therefore help ensure the presence of DNA in a high proportion of explanted embryos.
  • selectable DNA will be present mainly as non-integrated, non-replicating molecules; it should therefore be easy to isolate non- transgenic stem cells once selection is removed.
  • a nucleus is transferred from a donor cell to a recipient cell.
  • the use of this method is not restricted to a particular donor cell type.
  • the donor cell may be as described in Wilmut et al Nature 385 810 (1997); Campbell et al Nature 380 64-66 (1996); or Cibelli et al Science 280 1256-1258 (1998). All cells of normal karyotype, including embryonic, foetal and adult somatic cells which can be used successfully in nuclear transfer may in principle be employed in a method according to the present invention.
  • Foetal fibroblasts are a particularly useful class of donor cells.
  • Donor cells may be, but do not have to be, in culture and may be quiescent.
  • Nuclear donor cells which are quiescent are cells which can be induced to enter quiescence or exist in a quiescent state in vivo.
  • Cultured bovine primary fibroblasts, an embryo-derived ovine cell line (TNT4), an ovine mammary epithelial cell derived cell line (OME) from a 6 year old adult sheep, a fibroblast cell line derived from foetal ovine tissue (BLWF1) and an epithelial-like cell line derived from a 9-day old sheep embryo (SEC1) are described in WO 97/07669.
  • a class of embryo-derived cell lines useful in the invention which includes the TNT4 cell line described in WO 96/07732.
  • An example of a genetically modified donor cell is pOctneol described in McWhir et al (Nature Genetics 14 223-226 (1996)).
  • the mitotic cell cycle has four distinct phases, Gl, S, G2 and M.
  • the beginning event in the cell cycle, called start takes place in the Gl phase and has a unique function.
  • the decision or commitment to undergo another cell cycle is made at start.
  • Once a cell has passed through start it passes through the remainder of the Gl phase, which is the pre-DNA synthesis phase.
  • the second stage, the S phase is when DNA synthesis takes place. This is followed by the G2 phase, which is the period between DNA synthesis and mitosis. Mitosis itself occurs at the M phase.
  • Quiescent cells which include cells in which quiescence has been induced as well as those cells which are naturally quiescent, such as certain fully differentiated cells
  • Quiescent cells are generally regarded as not being in any of these four phases of the cycle; they are usually described as being in a GO state, so as to indicate that they would not normally progress through the cycle.
  • the nuclei of quiescent GO cells have a diploid DNA content.
  • Cultured cells can be induced to enter the quiescent state by various methods including chemical treatments, nutrient deprivation, growth inhibition or manipulation of gene expression. Presently the reduction of serum levels in the culture medium has been used successfully to induce quiescence in both ovine and bovine cell lines. In this situation, the cells exit the growth cycle during the Gl phase and arrest, as explained above, in the so-called GO stage. Such cells can remain in this state for several days (possibly longer depending upon the cell) until re-stimulated when they re-enter the growth cycle.
  • Quiescent cells arrested in the GO state are diploid. The GO state is the point in the cell cycle from which cells are able to differentiate.
  • the recipient cell to which the nucleus from the donor cell is transferred may be an oocyte or another suitable cell.
  • Recipient cells at a variety of different stages of development may be used, from oocytes at metaphase I through metaphase II, to zygotes and two-cell embryos. Each has its advantages and disadvantages.
  • the use of fertilized eggs ensures efficient activation whereas parthenogenetic activation is required with oocytes (see below).
  • Another mechanism that may favour the use of cleavage-stage embryos in some species is the extent to which reprogramming of gene expression is required. Transcription is initiated during the second cell cycle in the mouse and no major changes in the nature of the proteins being synthesised are revealed by two-dimensional electrophoresis until the blastocyst stage (Howlett & Bolton J. Embryol. Exp. Morphol. 87 175-206 (1985)). In most cases, though, the recipient cells will be oocytes.
  • the recipient be enucleate. While it has been generally assumed that enucleation of recipient oocytes in nuclear transfer procedures is essential, there is no published experimental confirmation of this judgement.
  • the original procedure described for ungulates involved splitting the cell into two halves, one of which was likely to be enucleated (Willadsen Nature 320 (6) 63-65 (1986)). This procedure has the disadvantage that the other unknown half will still have the metaphase apparatus and that the reduction in volume of the cytoplasm is believed to accelerate the pattern of differentiation of the new embryo (Eviskov et al, Development 109 322-328 (1990)).
  • recipient host cells to which the donor cell nucleus is transferred is an enucleated metaphase II oocyte, an enucleated unactivated oocyte or an enucleated preactivated oocyte. At least where the recipient is an enucleated metaphase II oocyte, activation may take place at the time of transfer. Alternatively, at least where the recipient is an enucleated unactivated metaphase II oocyte, activation may take place subsequently. As described above enucleation may be achieved physically, by actual removal of the nucleus, pro-nuclei or metaphase plate (depending on the recipient cell), or functionally, such as by the application of ultraviolet radiation or another enucleating influence.
  • cytoplast Enucleated oocyte recipients
  • MAGIC Recipient Metalphase Arrested G1/G0 Accepting Cytoplast
  • inactivated virus such as Sendai virus
  • electrical stimulation the use of electrical stimulation
  • Exposure of cells to fusion-promoting chemicals such as polyethylene glycol or other gly cols is a routine procedure for the fusion of somatic cells, but it has not been widely used with embryos.
  • polyethylene glycol is toxic it is necessary to expose the cells for a n inimum period and the need to be able to remove the chemical quickly may necessitate the removal of the zona pellucida (Kanka et al., Mol. Reprod. Dev. 29 110- 116 (1991)).
  • inactivated Sendai virus provides an efficient means for the fusion of cells from cleavage-stage embryos (Graham Wistar Inst. Symp. Monogr.
  • Sendai virus induces fusion in a proportion of cases, but is not sufficiently reliable for routine application (Willadsen Nature 320 (6) 63-65 (1986)). While cell-cell fusion is a preferred method of effecting nuclear transfer, it is not the only method that can be used. Other suitable techniques include microinjection (Ritchie and Campbell, J. Reproduction and Fertility Abstract Series No. 15, p60).
  • parthenogenetic activation Before or (preferably) after nuclear transfer (or, in some instances at least, concomitantly with it), it is generally necessary to stimulate the recipient cell into development by parthenogenetic activation, at least if the cell is an oocyte.
  • parthogenetic activation is more complicated than had been imagined. It had been assumed that activation is an all-or- none phenomenon and that the large number of treatments able to induce formation of a pronucleus were all causing "activation”.
  • exposure of rabbit oocytes to repeated electrical pulses revealed that only selection of an appropriate series of pulses and control of the Ca 2+ was able to promote development of diploidized oocytes to mid- gestation (Ozil Development 109 117-127 (1990)).
  • the interval between pulses in the rabbit is approximately 4 minutes (Ozil Development 109 117-127 (1990)), and in the mouse 10 to 20 minutes (Cutbertson & Cobbold Nature 316 541-542 (1985)), while there are preliminary observations in the cow that the interval is approximately 20 to 30 minutes (Robl et al, in Symposium on Cloning Mammals by Nuclear Transplantation (Seidel ed.), Colorado State University, 24-27 (1992)). In most published experiments activation was induced with a single electrical pulse, but new observations suggest that the proportion of reconstituted embryos that develop is increased by exposure to several pulses (Collas & Robl Biol. Reprod. 43 877-884 (1990)). In any individual case, routine adjustments may be made to optimise the number of pulses, the field strength and duration of the pulses and the calcium concentration of the medium.
  • the reconstituted embryo may be cultured in vitro or in vivo until the next stage of the method which is the derivation of the stem cell line from desired cells of the embryo, e.g. inner cell mass cells.
  • the embryo may be cultured to the blastocyst stage, or until the appearance of the primitive streak, i.e. until the end of the period of 14 days beginning with the day on which the nuclear transfer occurred, not counting any time during which the embryo is stored or prior to activation.
  • the differentiated cells may be derived from the embryo as explanted into the (generally in vitro) culture or may result from the differentiation of ES cells within the embryo. The intention will generally be to selectively kill all differentiated cells. The killing of the differentiated cells may also be termed as being selective ablation.
  • Explanted embryos will generally contain undifferentiated ES progenitor cells as well as differentiated cells such as trophectoderm and endoderm cells.
  • the explanted embryo may be obtained, as outlined by Robertson (1987) loc. cit. , from an in vitro culture or from an in vivo host by abstracting an embryo from the uterus (for example at the blastocyst stage) and culturing in a suitable medium over a layer of feeder cells, which may be mitotically inactivated fibroblasts, as previously described.
  • the explanted embryo on which the selective killing step of the invention is performed may have gone through one or more passages in which a clump of predominantly undifferentiated cells is isolated, disaggregated and replated onto a new feeder layer.
  • Methods in accordance with the present invention may therefore also include the step of culturing the resulting undifferentiated embryonic cells after the step of selective killing of differentiated cells.
  • the differentiated cells are killed by means of a drug selection regime.
  • the regime may be used to kill differentiated cells during early passages of the explanted embryo.
  • Undifferentiated ES cells may express a resistance marker for a toxic drug, so that when the colony is exposed to the drug only the differentiated cells are killed.
  • the use of a promoter specific or substantially specific for undifferentiated cells is important, and the embryo cells can be made transgenic for, or otherwise be able to express, a construct comprising such a promoter operatively coupled to a DNA sequence encoding the drug resistance marker.
  • the transcription factor Oct-3/4 was first identified as present in undifferentiated mouse embryonal carcinoma (EC) cells (closely related to ES cells) but not in their differentiated derivatives (Okamoto et al , Cell 60 461-472 (1990)). Analysis of Oct- 3/4 mRNA expression in mouse showed that it was restricted to undifferentiated ES and EC cells (Ben-Shusan et al , Mol. Cell. Biol. 13 891-901 (1993)), embryo inner cell mass and primordial germ cells (Rosner et al , Nature 345 686-92 (1990)).
  • the Oct- 3/4 promoter is capable of conferring Oct-3/4 specific expression on a heterologous reporter gene in transgenic mouse embryos (Okazawa et al.
  • neo aminoglycoside phosphotransferase
  • the hygro, his, dhfr, gpt, gs or ada genes could also be used, as could any other suitable drug resistance gene.
  • gene in this context does not imply that natural genomic DNA has to be used, although that may be preferred.
  • cDNAs may be at least as suitable, as may "rulnigenes'' which contain some, but not all, of the introns which may naturally be present in the gene.
  • a DNA sequence whose expression gives rise to cell death is selectively expressed in differentiated cells.
  • a promoter specific or substantially specific for differentiated cells is important, and the embryo cells can be made transgenic for, or otherwise be able to express, a construct comprising such a promoter operatively coupled to the lethal DNA sequence (for example that encoding the toxin).
  • One suitable promoter is that of the fransforrning growth factor ⁇ -2 gene, which is activated on differentiation of ES cells independent of the cell type formed (Mummery et al , Dev. Biol. 137 161-170 (1990)).
  • Genes encoding various toxins may be placed under the control of a promoter active in differentiated cells.
  • the Diphtheria toxin subunit-A gene Maxwell et al. , Mol. Cell. Biol. 7 1576-1589 (1987)
  • the Ricin toxin subunit-A gene Landel et al, Genes and Dev. 2 1168-1178 (1988)
  • the natural gene or a non-natural sequence encoding the toxin may be used.
  • Embryos which can express either (a) a selectable marker gene under the control of a promoter expressed specifically in undifferentiated ES cells and/or (b) a toxin gene under the control of a promoter expressed specifically in differentiated cells can be generated using standard methods.
  • Such embryos may be transgenic, in that a heterologous DNA construct may be stably integrated in the embryonic genome, or they may simply contain non-integrated expressible DNA.
  • ES cells may then be derived from these transgenic, injected or transfected embryos by culture under selective conditions.
  • the selectable marker or toxin gene construct can, if necessary or desirable, be removed.
  • the removal is, in effect, automatic.
  • more deliberate steps have to be taken.
  • site specific recombination systems to generate precisely defined deletions in cultured mammalian cells has recently been demonstrated. Gu et al. (Cell 73 1155-1164 (1993)) describe how a deletion in the immunoglobulin switch region in mouse ES cells was generated between two copies of the bacteriophage PI loxP site by transient expression of the Cre site-specific recombinase, leaving a single loxP site.
  • yeast FLP recombinase has been used to precisely delete a selectable marker defined by recombinase target sites in mouse erythroleukemia cells (Fiering et al , Proc. Nat'l. Acad. Sci. USA 90 8469-8473 (1993)).
  • the Cre lox system is exemplified below, but other site-specific recombinase systems could be used.
  • a construct used in the Cre lox system will usually have the following three functional elements:
  • a negative selectable marker e.g. Herpes simplex virus thymidine kinase (TK) gene
  • TK Herpes simplex virus thymidine kinase
  • ubiquitously expressed promoter e.g. phosphoglycerate kinase (Soriano et al , Cell 64 693-702 (1991)
  • This construct can be eliminated from established stem cell lines, for example ES cell or EG cell lines, containing it by means of site specific recombination between the two loxP sites mediated by Cre recombinase protein which can be introduced into the cells by lipofection (Baubonis et al , Nuc. Acids Res. 21 2025-2029 (1993)). Cells which have deleted DNA between the two loxP sites are selected for loss of the TK gene (or other negative selectable marker) by growth in medium containing the appropriate drug (ganciclovir in the case of TK).
  • Totipotent stem cells can be used as a means of manipulating an animal's genome either by simple introduction of a transgene or by the more extensive modifications possible using gene targeting technology.
  • transgenic animal stem cells For the production of a genetically modifed cell line, it is necessary that any genetic changes introduced into the animal stem cells are transmitted to the next generation.
  • the preparation of transgenic animal stem cells according to the present invention has several advantages over the use of somatic cells as described in the more traditional nuclear transfer procedures. Firstly, the animal stem cells have the potential to transmit the genetic modification to the next generation by both chimaera formation and nuclear transfer. This is an important advantage as the technique of traditional nuclear transfer is still at an early stage and some animal species may pose particular problems and there is the possibility that results in animals other than sheep and cows may be different. Secondly, somatic cells cannot contribute to the development of a germ line chimaeric animal.
  • somatic cells undergo homologous recombination at a lower rate than ES cells (Arbones et al Nature Genetics 6 90-97 (1994); Thyagaraja et al Nucl. Acids Res. 24 4084-4091 (1996)). Assuming that ES and EG cells have roughly similar targeting frequencies, the animal stem cells of the present invention should target at a higher frequency than somatic cells.
  • human stem lines preferably ES or EG cell lines
  • This offers the opportunity to prepare stem cell-derived somatic cells for potential transplantation therapy in a variety of human conditions.
  • the resulting cells would be expected to induce little or no immune response in patients as chromosomally identical lines could be matched to each patient.
  • the cells will be differentiated derivatives of the stem cell or stem cell line of the present invention.
  • transgenic bovine neurons can be generated from bovine embryos reconstituted by nuclear transfer from foetal fibroblasts and used to treat a rat model of Parkinson's disease. They have not, however, sought to engineer the foetal fibroblast to enable subsequent ES isolation.
  • a stem cell line prepared in accordance with the first aspect of the invention may suitably be an embryonic cell line or an embryonic germ cell line.
  • Stem cells and stem cell lines prepared in accordance with a method of the present invention may have widespread uses in medicine in the therapy and/or prophylaxis of diseases.
  • such cells or their differentiated derivatives can be used in the treatment of a diverse range of medical conditions characterised by the native cell population of a patient failing to perform its usual function sufficiently or even at all, e.g.
  • Cells prepared in accordance with the present invention may also find application in the treatment of degenerative disorders, e.g. neurodegenerative disorders such as Alzheimer's disease or Motor Neurone Disease.
  • the present invention therefore also includes methods of treatment of diseases in which a viable, therapeutically effective population of stem cells prepared in accordance with the first aspect of the invention or their differentiated derivatives are transplanted into a patient suffering from a disease characterised by a loss of or absence of normal cell function.
  • This aspect of the invention also therefore includes the use of such cells in the transplantation and the use of such cells in the preparation of a therapeutic or prophylactic agent in the treatment of a disease in a patient characterised by a loss of normal cell function.
  • the use of cells in therapy by transplantation is not limited to the preparation of allogeneic cell populations, but also includes the use of autologous cell populations from the patient and xenogeneic cell populations from another animal species.
  • the cells may also preferably be further transgenically modified by methods known in the art to reduce the risks of immune rejection by the patient.
  • the stem cell lines and stem cells prepared in accordance with the present invention may also find further application as an alternative source of nuclear donor cells for additional nuclear transfer procedures. These procedures may lead to the production of new embryos which are allowed to develop normally for the production of an animal. Such cells and embryos may also be the subject of further intervention to introduce further transgenes.
  • a new ES cell line of the present invention may act as a source of nuclear donor cells for use in further rounds of nuclear transfer.
  • a method for preparing an animal comprising:
  • step (d) in the method of this aspect of the invention is to cause an animal to develop to term from the embryo. This may be done directly or indirectly. In direct development, the reconstituted embryo from step (a) is simply allowed to develop without further intervention beyond any that may be necessary to allow the development to take place. In indirect development, however, the embryo may be further manipulated before full development takes place. For example, the embryo may be split and the cells clonally expanded, for the purpose of improving yield.
  • each embryo that does develop itself can be used as a nuclear donor, such as, for example at the morula or 32-64 cell stage; alternatively, inner cell mass cells can be used at the blastocyst stage. Embryos derived from these subsequent transfers could themselves also be used as potential nuclear donors to further increase efficiency.
  • each developing embryo may be multiplied in this way by the efficiency of the nuclear transfer process.
  • the degree of enhancement likely to be achieved depends upon the cell type. In sheep, it is readily possible to obtain 55% blastocyst stage embryos by transfer of a single blastomere from a 16 cell embryo to a preactivated "Universal Recipient" oocyte. So it is reasonable to hypothesise that each embryo developed from a single cell could give rise to eight at the 16 cell stage. Although these figures are just a rough guide, it is clear that at later developmental stages the extent of benefit would depend on the efficiency of the process at that stage.
  • a chimaeric animal formed from cells derived from a naturally formed embryo and an embryo reconstructed by nuclear transfer.
  • a chimaera can be formed by taking a proportion of cells of the natural embryo and a proportion of the cells of the reconstructed embryo at any stage up to the blastocyst stage and fo ⁇ ning a new embryo by aggregation or injection.
  • the proportion of cells may be in the ratio of 50:50 or another suitable ratio to achieve the formation of an embryo which develops to term. The presence of normal cells in these circumstances is thought to assist in rescuing the reconstructed embryo and allowing successful development to term and a live birth.
  • the reconstituted embryo may be cultured, in vivo or in vitro to the blastocyst stage, or until the appearance of the primitive streak, i.e. until the end of the period of 14 days beginning with the day on which the nuclear transfer occurred, not counting any time during which the embryo is stored or prior to activation.
  • the embryo in order to protect the embryo it should preferably be embedded in a protective medium such as agar before transfer and then dissected from the agar after recovery from the temporary recipient.
  • a protective medium such as agar before transfer and then dissected from the agar after recovery from the temporary recipient.
  • the function of the protective agar or other medium is twofold: first, it acts as a structural aid for the embryo by holding the zona pellucida together; and secondly it acts as barrier to cells of the recipient animal's immune system.
  • the embryo may be screened for suitability for development to term. Typically, this will be done where the embryo is transgenic and screening and selection for stable integrants has been carried out. Screening for non-transgenic genetic markers may also be carried out at this stage. However, because the method of the invention allows for screening of donors at an earlier stage, that will generally be preferred.
  • blastocyst embryo After screening, if screening has taken place, the blastocyst embryo is allowed to develop to term. This will generally be in vivo. If development up to blastocyst has taken place in vitro, then transfer into the final recipient animal takes place at this stage. If blastocyst development has taken place in vivo, although in principle the blastocyst can be allowed to develop to term in the pre-blastocyst host, in practice the blastocyst will usually be removed from the (temporary) pre-blastocyst recipient and, after dissection from the protective medium, will be transferred to the (permanent) post- blastocyst recipient.
  • animals may be bred from the animal prepared by the preceding steps.
  • an animal may be used to establish a herd or flock of animals having the desired genetic characteristic(s).
  • Animals produced by transfer of nuclei from a source of genetically identical cells share the same nucleus, but are not strictly identical as they are derived from different oocytes. The significance of this different origin is not clear, but may affect commercial traits.
  • transgenic animals according to this aspect of the invention should be construed in conformity with the discussion of the term transgenic as used above in relation to animal stem cells.
  • transgenesis may also be employed by transfection with suitable constructs, with or without selectable markers;
  • (6a) optionally screen and select for stable integrants - omit if done at (3) - or other desired characteristics;
  • stem cell isolation under conditions of selective killing of differentiated cells (for example ES or EG cell isolation);
  • an animal prepared as described above there is provided an animal prepared as described above.
  • the invention is therefore equally applicable in the production of transgenic, as well as non-transgenic animals.
  • Transgenic animals may be produced from genetically altered donor cells.
  • transgenic animals according to this aspect of the invention should be construed in conformity with the discussion of the term transgenic as used above in relation to animal stem cells.
  • the overall procedure has a number of advantages over conventional procedures for the production of transgenic (i.e. genetically modified) animals which may be summarised as follows: (1) fewer recipients will be required;
  • a line of transgenic mice has been generated previously which carry 1.94kb fragment of the 5' Oct promoter juxtaposed with a fragment encoding neomycin phosphotransferase and designated pOctoneol. Embryos from this line have been shown to be non-permissive for ES isolation by standard techniques and permissive under conditions of selective ablation at a frequency of 10% (McWhir et al Nature Genetics 14 223-226 (1996)). As a consequence, foetal fibroblasts derived from pOctneol mice constitute the ideal nuclear donor as the efficacy of the transgene has already been proven. Hence, inappropriate transgene expression due to site of incorporation effects is not anticipated.
  • Octneol foetal fibroblasts will be isolated from day 13 foetuses by incubation with trypsin and vigorous pipetting. The resulting cell suspension will be plated onto 10cm plates (1 foetus per plate).
  • Example 2 Preparation of nuclear donor cells from Octneol foetal fibroblasts and nuclear transfer
  • Octneol foetal fibroblasts will be prepared as nuclear donor cells at the earliest convenient passage according to the teaching of Campbell et al. (1997. Nature 380,64).
  • Example 3 Preparation of ES cell line from reconstructed embryos Reconstructed embryos will be cultured to blastocyst stage and implanted into culture for ES isolation by selective ablation according to the teachings of McWhir et al Nature Genetics 14 223-226 (1996)).
  • Reconstructed embryos prepared as described above are transferred to recipient females.
  • Females are sacrificed at stages between 8.5 and 10.5 days of development and the primordial germ cells harvested for explantation into culture and subsequent isolation of EG lines. Culture conditions are described in Labonski et al (1994), with the addition of 50 ⁇ g/ml G418.
  • ES and EG cell lines isolated as described above are injected into blastocysts as described in Bradley (Bradley, A., Production and analysis of chimaeric mice in "Teratocarcinomas and embryonic stem cells - A practical approach", ed. Robertson, E. J., IRL Press, Oxford (1987)). Injected embryos are transferred to recipient females and the resultant chimaeric pups are test bred or the detection of germline transmission through coat colour markers. Germline pups as indicated by coat colour are tested by Southern analysis for transmission of the pOctneol transgene.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention porte sur un procédé permettant de préparer des cellules de souche animale. A cet effet, on commence par reconstituer un embryon d'animal en transférant le noyau d'une cellule donneuse dans une cellule acceptrice appropriée. On tue ensuite de façon sélective des cellules de différenciation de l'embryon, puis on met en culture les cellules embryonnaires indifférenciées résultantes.
PCT/GB1999/001738 1998-06-02 1999-06-01 Obtention de lignees de cellules de souches embryonnaires issues de cellules somatiques par reconstruction des embryons et ablation selective WO1999063061A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42755/99A AU4275599A (en) 1998-06-02 1999-06-01 Es cell lines from somatic cells via embryo reconstruction and selective ablation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9811859.9 1998-06-02
GBGB9811859.9A GB9811859D0 (en) 1998-06-02 1998-06-02 Biological manipulation

Publications (1)

Publication Number Publication Date
WO1999063061A1 true WO1999063061A1 (fr) 1999-12-09

Family

ID=10833084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/001738 WO1999063061A1 (fr) 1998-06-02 1999-06-01 Obtention de lignees de cellules de souches embryonnaires issues de cellules somatiques par reconstruction des embryons et ablation selective

Country Status (3)

Country Link
AU (1) AU4275599A (fr)
GB (1) GB9811859D0 (fr)
WO (1) WO1999063061A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
WO2011133889A2 (fr) 2010-04-23 2011-10-27 Cold Spring Harbor Laboratory Sharn présentant une nouvelle conception structurelle

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020042A1 (fr) * 1994-01-25 1995-07-27 Ppl Therapeutics (Scotland) Limited Isolement de cellules souche embryonnaires
WO1997037009A1 (fr) * 1996-04-01 1997-10-09 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, Represented By Its Amherst Campus Lignees de cellules a bouton embryonnaire cultive, derivees d'embryons d'ongules
WO1998007841A1 (fr) * 1996-08-19 1998-02-26 University Of Massachusetts Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire croisee d'especes
WO1998030683A2 (fr) * 1997-01-10 1998-07-16 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts Transfert nucleaire au moyen de cellules donneuses foetales et adultes differentiees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020042A1 (fr) * 1994-01-25 1995-07-27 Ppl Therapeutics (Scotland) Limited Isolement de cellules souche embryonnaires
WO1997037009A1 (fr) * 1996-04-01 1997-10-09 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, Represented By Its Amherst Campus Lignees de cellules a bouton embryonnaire cultive, derivees d'embryons d'ongules
WO1998007841A1 (fr) * 1996-08-19 1998-02-26 University Of Massachusetts Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire croisee d'especes
WO1998030683A2 (fr) * 1997-01-10 1998-07-16 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts Transfert nucleaire au moyen de cellules donneuses foetales et adultes differentiees

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIBELLI J.B. ET AL: "Cloned transgenic calves produced from nonquiescent fetal fibroblasts", SCIENCE, vol. 280, May 1998 (1998-05-01), pages 1256 - 1258, XP002087435 *
MCWHIR J: "selective ablation of differentiated cells permits isolation of embryonic stem cell lines from murine embryos with a non permissive genetic background", NATURE GENETICS, vol. 14, 1996, pages 223 - 226, XP002087434 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US8426198B2 (en) 2000-11-27 2013-04-23 Geron Corporation In vitro differentiated cell and human embryonic stem cell population
US9023645B2 (en) 2000-11-27 2015-05-05 Asterias Biotherapeutics, Inc. Isolated in vitro cell population comprising primate pluripotent stem cells containing a nucleic acid construct and differentiated progeny of the pluripotent stem cells
WO2011133889A2 (fr) 2010-04-23 2011-10-27 Cold Spring Harbor Laboratory Sharn présentant une nouvelle conception structurelle
EP3502254A1 (fr) 2010-04-23 2019-06-26 Cold Spring Harbor Laboratory Nouveaux arnsh structurellement conçus

Also Published As

Publication number Publication date
AU4275599A (en) 1999-12-20
GB9811859D0 (en) 1998-07-29

Similar Documents

Publication Publication Date Title
US7355094B2 (en) Methods of ungulate nuclear transfer
KR100743006B1 (ko) 핵이식용 세포질 수용체로서의 불활성화 난모 세포
US7598082B1 (en) Process of mammalian cell reprogramming through production of a heterokaryon
US20020012655A1 (en) Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease
US20010039667A1 (en) Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease
WO1999063061A1 (fr) Obtention de lignees de cellules de souches embryonnaires issues de cellules somatiques par reconstruction des embryons et ablation selective
CA2336437A1 (fr) Reprogrammation cellulaire par production d'heterocaryon
AU771102B2 (en) Cell reprogramming
GB2331751A (en) Quiescent cell populations for nuclear transfer
US20120076761A1 (en) Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including Parkinson's disease
AU2003271356B9 (en) Quiescent cell population for nuclear transfer
MXPA98001645A (en) Oocytes inactivated as receptors of cytopllasto for nuclear transfer
AU2005246962A1 (en) Quiescent cell population for nuclear transfer
MXPA00000201A (en) Cloning using donor nuclei from non-serum starved, differentiated cells
AU4277400A (en) A process of cell reprogramming through production of a heterokaryon
MXPA98001646A (en) Cellular populations inactive for transfer celu

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase